Frovatriptan is a synthetic triptan and a specialty chemical used primarily as an active pharmaceutical ingredient (API) in the treatment of acute migraine attacks in adults. It is a selective agonist for serotonin (5-HT_1B/1D) receptors, with the chemical formula C₁₄H₁₇N₃O and CAS number 158747-02-5. By constricting blood vessels in the brain and inhibiting the release of pro-inflammatory neuropeptides, it alleviates migraine symptoms including headache, nausea, vomiting, photophobia, and phonophobia. Frovatriptan is noted for its longer half-life (approximately 26 hours) compared to other triptans, providing prolonged relief suitable for extended migraine episodes, though it has a slower onset of action (2-4 hours). It is typically administered orally at the onset of symptoms and is not indicated for migraine prevention or cluster headaches. As a reagent, it is supplied at high purity (e.g., 98%) for pharmaceutical research, synthesis, or formulation development. Consult healthcare professionals for clinical use and follow safety guidelines to avoid side effects such as dizziness, fatigue, or chest tightness.